Figure 3
Proposed antithrombotic algorithm after valvular heart procedures. aIncludes atrial fibrillation, previous thromboembolic events, left ventricular dysfunction and older generation mechanical AVR; bstands for replacement or repair. ASA: acetylsalicylic acid; AVR: aortic valve replacement; DAPT: dual antiplatelet therapy; INR: international normalized ratio; LMWH: low-molecular-weight heparin; MVR: mitral valve replacement; OAC: oral anticoagulant; SAPT: single antiplatelet therapy; TAVI: transcatheter aortic valve implantation; TVR: tricuspid valve replacement; UFH: unfractionated heparin; VKA: vitamin-K antagonists.

Proposed antithrombotic algorithm after valvular heart procedures. aIncludes atrial fibrillation, previous thromboembolic events, left ventricular dysfunction and older generation mechanical AVR; bstands for replacement or repair. ASA: acetylsalicylic acid; AVR: aortic valve replacement; DAPT: dual antiplatelet therapy; INR: international normalized ratio; LMWH: low-molecular-weight heparin; MVR: mitral valve replacement; OAC: oral anticoagulant; SAPT: single antiplatelet therapy; TAVI: transcatheter aortic valve implantation; TVR: tricuspid valve replacement; UFH: unfractionated heparin; VKA: vitamin-K antagonists.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close